Bruker Corporation (NASDAQ:BRKR) Stock Has Consensus Target Price of $59.43

Bruker Corporation (NASDAQ:BRKR) has been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $60.57.

A number of analysts have weighed in on BRKR shares. Leerink Partners boosted their price target on Bruker from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday. Zacks Research lowered Bruker from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 2nd. Citigroup raised their price objective on Bruker from $53.00 to $64.00 and gave the company a “hold” rating in a research note on Thursday. Guggenheim boosted their target price on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Finally, TD Cowen upped their target price on Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th.

Bruker Stock Up 5.6%

BRKR stock opened at $61.31 on Tuesday. The company has a current ratio of 1.84, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74. Bruker has a 1 year low of $32.37 and a 1 year high of $68.98. The company has a fifty day simple moving average of $59.01 and a 200 day simple moving average of $50.59. The firm has a market cap of $9.34 billion, a PE ratio of -55.74, a PEG ratio of 1.79 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.42 by $0.14. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. The firm had revenue of $874.00 million for the quarter, compared to the consensus estimate of $865.16 million. During the same period in the prior year, the business posted $0.45 earnings per share. The business’s quarterly revenue was up 1.6% on a year-over-year basis. Sell-side analysts anticipate that Bruker will post 2.13 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -18.18%.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the sale, the vice president directly owned 134,806 shares in the company, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Pallas Capital Advisors LLC acquired a new position in shares of Bruker during the second quarter valued at about $570,746,000. Edmond DE Rothschild Holding S.A. acquired a new stake in Bruker during the second quarter worth about $169,899,000. Primecap Management Co. CA acquired a new stake in Bruker during the second quarter worth about $53,145,000. Bank of New York Mellon Corp acquired a new stake in Bruker during the second quarter worth about $44,839,000. Finally, Old West Investment Management LLC acquired a new position in shares of Bruker in the second quarter valued at $40,146,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.